Psychopharmacology

Psychopharmacology investigates how chemical agents influence brain function, behaviour and mental health. It encompasses early sedatives and stimulants, the mid-twentieth century revolution initiated by antipsychotics, antidepressants and mood stabilisers, and contemporary strategies targeting neurotransmitter systems, intracellular signalling and neuroimmune pathways. Core objectives include alleviating symptoms of disorders such as depression, anxiety and schizophrenia, restoring functional neural circuitry and minimising adverse effects. Progress has relied on serendipitous discoveries—such as chlorpromazine’s calming action or lithium’s antimanic properties—followed by systematic refinement of drug classes to improve selectivity, predictability and tolerability. Advances in molecular neuroscience, receptor pharmacology and immunopsychiatry have yielded agents that modulate synaptic plasticity, inflammatory cascades and neurotrophic support. Emerging therapies aim to restore excitatory–inhibitory balance, harness endogenous repair mechanisms and tailor treatments through biomarkers and precision medicine approaches. Psychopharmacology thus stands at the intersection of chemistry, neurobiology and clinical psychiatry, striving to translate mechanistic insights into effective, safe interventions.

Research from Nature Portfolio

Studies of immune–neural interactions have illuminated how T cell activation and deficits in regulatory T cells contribute to the pathophysiology and severity of major depressive disorder. Peripheral and central markers of T helper-1 and inflammatory profiles correlate with clinical ratings, suggesting that restoring Treg homeostasis may ameliorate neuroimmunotoxicity and depressive symptoms. In first-episode major dysmood disorder, adverse life events drive physiosomatic and chronic fatigue–fibromyalgia symptoms via elevated cytokines—particularly interleukin-16 and IL-8—and reduced immunoregulatory factors, highlighting immune activation as a mediator of mood and somatic phenomenology. These insights point to immunomodulatory strategies as adjuncts to standard antidepressant or mood-stabilising regimens.

Psychopharmacology publication trend

The graph below shows the total number of articles in psychopharmacology across all publications each year (not limited to Nature Index journals).

Technical terms

Regulatory T (Treg) cell: A subset of T lymphocytes that suppresses immune activation and maintains tolerance.

Cytokines: Signalling proteins released by immune cells that modulate inflammation and neural function.

eEF2 dephosphorylation: Removal of a phosphate group from eukaryotic elongation factor 2, increasing translation of synaptic proteins.

mTORC1 signalling: Activation of a kinase complex that promotes protein synthesis crucial for synaptic growth and plasticity.

M2 muscarinic AChR: Acetylcholine receptor subtype 2 which regulates neuronal excitability and neurotrophic cascades.

Synaptic plasticity: The dynamic strengthening or weakening of synaptic connections underpinning learning, memory and mood regulation.

References

1. T cell activation and deficits in T regulatory cells are associated with major depressive disorder and severity of depression. Scientific Reports (2024).
2. In major dysmood disorder, physiosomatic, chronic fatigue and fibromyalgia symptoms are driven by immune activation and increased immune-associated neurotoxicity. Scientific Reports (2024).
3. Subchronic administration of scopolamine reverses UCMS-induced behavior in mice via eEF2 protein dephosphorylation. Pharmacological Reports (2024).
4. M2-AChR Mediates Rapid Antidepressant Effects of Scopolamine Through Activating the mTORC1-BDNF Signaling Pathway in the Medial Prefrontal Cortex. Frontiers in Psychiatry (2021).
5. Cell-type-specific synaptic modulation of mAChR on SST and PV interneurons. Frontiers in Psychiatry (2023).